Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jens Bedke

Showing results (1-10 of 262) with videos related to

Pageof 27
Sort By:
The New England Journal of Medicine|December 10, 2025
Disitamab Vedotin plus Toripalimab - New Players in Urothelial CarcinomaJens Bedke
European Urology|March 27, 2024
Re: Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial CarcinomaConstantin Tilgener, Jens Bedke
Expert Review of Anticancer Therapy|November 13, 2013
Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?Jens Bedke, Arnulf Stenzl
European Urology|December 3, 2013
Re: validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohortJens Bedke, Arnulf Stenzl
European Urology|February 13, 2016
Words of Wisdom. Re: Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaJens Bedke, Arnulf Stenzl
European Urology|April 25, 2021
Re: Enfortumab Vedotin in Previously Treated Advanced Urothelial CarcinomaJens Bedke, Moritz Maas
Urologie (Heidelberg, Germany)|November 15, 2024
[Adjuvant therapy for renal cell carcinoma : Relevant patient and tumor factors]Jens Bedke, Viktor Grünwald
Lancet (London, England)|July 31, 2023
TNM-based risk eligibility for adjuvant trials in renal cell carcinomaJens Bedke, Axel Bex
Aktuelle Urologie|November 25, 2015
[Not Available]Jens Bedke, Stephan Kruck
Nature Reviews. Urology|May 12, 2010
Immunologic mechanisms in RCC and allogeneic renal transplant rejectionJens Bedke, Arnulf Stenzl
Pageof 27

Showing results (1-10 of 262) with videos related to

Sort By:
Pageof 27
The New England Journal of Medicine|December 10, 2025
Disitamab Vedotin plus Toripalimab - New Players in Urothelial CarcinomaJens Bedke
European Urology|March 27, 2024
Re: Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial CarcinomaConstantin Tilgener, Jens Bedke
Expert Review of Anticancer Therapy|November 13, 2013
Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?Jens Bedke, Arnulf Stenzl
European Urology|December 3, 2013
Re: validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohortJens Bedke, Arnulf Stenzl
European Urology|February 13, 2016
Words of Wisdom. Re: Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaJens Bedke, Arnulf Stenzl
European Urology|April 25, 2021
Re: Enfortumab Vedotin in Previously Treated Advanced Urothelial CarcinomaJens Bedke, Moritz Maas
Urologie (Heidelberg, Germany)|November 15, 2024
[Adjuvant therapy for renal cell carcinoma : Relevant patient and tumor factors]Jens Bedke, Viktor Grünwald
Lancet (London, England)|July 31, 2023
TNM-based risk eligibility for adjuvant trials in renal cell carcinomaJens Bedke, Axel Bex
Aktuelle Urologie|November 25, 2015
[Not Available]Jens Bedke, Stephan Kruck
Nature Reviews. Urology|May 12, 2010
Immunologic mechanisms in RCC and allogeneic renal transplant rejectionJens Bedke, Arnulf Stenzl
Pageof 27